이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

AbbVie 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	1.5yrs
이사회 평균 재임 기간	11.5yrs

최근 관리 업데이트

Recent updates

CEO

AbbVie 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Richard Gonzalez	Executive Chairman	11.5yrs	US$25.66m	0.031% $ 87.2m
Robert Michael	CEO, President	2.1yrs	US$14.44m	0.0056% $ 15.7m
Scott Reents	Executive VP & CFO	2.1yrs	US$10.19m	0.00087% $ 2.4m
Azita Saleki-Gerhardt	Executive VP & COO	less than a year	US$9.30m	0.013% $ 36.0m
Jeffrey Stewart	Executive VP & Chief Commercial Officer	no data	US$15.35m	0.0035% $ 9.9m
Thomas Hudson	Senior VP & Chief Scientific Officer of Global Research	no data	데이터 없음	0.0061% $ 17.0m
Elizabeth Shea	Senior Vice President of Investor Relations	no data	데이터 없음	데이터 없음
Perry Siatis	Executive VP	1.8yrs	데이터 없음	0% $ 0
Sanjay Narayan	Senior VP	less than a year	데이터 없음	데이터 없음
Timothy Richmond	Executive VP & Chief Human Resources Officer	no data	US$3.30m	0.00078% $ 2.2m
Wulff-Erik von Borcke	Senior VP of AbbVie & President of Oncology	less than a year	데이터 없음	데이터 없음
Nicholas Donoghoe	Executive VP and Chief Business & Strategy Officer	1.5yrs	데이터 없음	0.0032% $ 8.9m

1.5yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 관리: 4AB0 의 관리팀은 경험 (평균 재직 기간 1.5 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Richard Gonzalez	Executive Chairman	11.5yrs	US$25.66m	0.031% $ 87.2m
Roxanne Austin	Independent Director	11.5yrs	US$388.39k	0.00065% $ 1.8m
Thomas Freyman	Independent Director	4.2yrs	US$389.98k	0.0071% $ 19.9m
Glenn Tilton	Lead Independent Director	11.5yrs	US$421.58k	0.0014% $ 4.0m
Edward Rapp	Independent Director	11.5yrs	US$394.98k	0.00091% $ 2.6m
William H. Burnside	Independent Director	11.5yrs	US$377.48k	0% $ 0
Frederick Waddell	Independent Director	11.5yrs	US$369.98k	0.00011% $ 308.8k
Melody Meyer	Independent Director	7.2yrs	US$369.98k	0% $ 0
Brett Hart	Independent Director	8.5yrs	US$384.98k	0% $ 0
Rebecca Roberts	Independent Director	6.2yrs	US$359.98k	데이터 없음
Robert Alpern	Independent Director	11.5yrs	US$461.18k	0.000010% $ 28.1k
Jennifer Davis	Independnet Director	less than a year	US$45.00k	데이터 없음

11.5yrs

평균 재임 기간

70yo

평균 연령

경험이 풍부한 이사회: 4AB0 의 이사회는 노련하고 경험이 있습니다(평균 재직 기간 11.4 년).

AbbVie 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

AbbVie Announces Board Changes

AbbVie Inc. Announces Board of Directors Changes

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie Inc. Announces Chief Executive Officer Changes

Recent updates

AbbVie Announces Board Changes

AbbVie Receives Positive CHMP Opinion for Epcoritamab (Tepkinly) for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma

U.S. Food and Drug Administration Grants Second Approval for AbbVie's EPKINLY (epcoritamab-bysp) to Treat Patients with Relapsed or Refractory Follicular Lymphoma

AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024

AbbVie Inc. Announces Board of Directors Changes

AbbVie Inc. Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab Soravtansine (ELAHERE®) for High Folate Receptor-Alpha (FRa) Expressing Platinum-Sensitive Ovarian Cancer

AbbVie Advances Oncology Pipeline with Start of Multiple Myeloma Phase 3 Clinical Trial for Investigational Asset ABBV-383

AbbVie Receives Positive CHMP Opinion for Risankizumab (SKYRIZI) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis

AbbVie Inc. (NYSE:ABBV) completed the acquisition of Landos Biopharma, Inc. (NasdaqCM:LABP) from a group of shareholders.

Health Canada Approves QULIPTA (atogepant) for the Preventive Treatment of Chronic Migraine in Adults

Abbvie Inc. Announces Board Changes, Effective July 1, 2024

AbbVie Inc. Announces Positive Topline Results from Level Up

AbbVie Announces Positive Top-Line Results from SELECT-GCA Study of Upadacitinib (RINVOQ) Showed Positive Results in Patients with Giant Cell Arteritis

AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine

AbbVie Inc. to Report Q1, 2024 Results on Apr 26, 2024

AbbVie Inc. (NYSE:ABBV) signed a definitive agreement to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) for approximately $110 million.

AbbVie Inc. (NYSE:ABBV) agreed to acquire Landos Biopharma, Inc. (NasdaqCM:LABP) on March 24, 2024.

AbbVie Announces U.S. Food and Drug Administration Grants Full Approval for ELAHERE® (mirvetuximab soravtansine-gynx) for Certain Ovarian Cancer Patients

AbbVie Inc., Annual General Meeting, May 03, 2024

AbbVie and Allergan Aesthetics to Present New Data at 2024 Annual AAD Meeting Showcasing Depth and Strength Across Dermatology and Aesthetics Portfolios

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

AbbVie Inc. Announces Chief Executive Officer Changes

AbbVie Inc. Declares Quarterly Cash Dividend, Payable on May 15, 2024

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie Inc. (NYSE:ABBV) completed the acquisition of ImmunoGen, Inc. (NasdaqGS:IMGN) from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc. (NYSE:BLK), State Street Corporation (NYSE:STT), The Vanguard Group, Inc. and others.

AbbVie's VYALEV™? (foslevodopa/Foscarbidopa Solution) Available for the Treatment of Advanced Parkinson's Disease in Canada

AbbVie Inc. Reports Unaudited Intangible Asset Impairment for the Quarter Ended December 31, 2023

AbbVie Inc. Launches Produodopa (Foslevodopa/Foscarbidopa) for People Living with Advanced Parkinson's Disease in the European Union

Abbvie Inc. Announces Phase 2 Results Showing Adults with Moderate to Severe Hidradenitis Suppurativa

AbbVie Inc. to Report Q4, 2023 Results on Feb 02, 2024

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire Cerevel Therapeutics Holdings, Inc. (NasdaqCM:CERE) for $8.2 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.5 billion.

AbbVie Inc. (NYSE:ABBV) entered into a definitive agreement to acquire ImmunoGen, Inc. (NasdaqGS:IMGN) for $8.4 billion.

AbbVie Inc. Announces Positive Topline Results from Phase 2 Luminosity Trial Evaluating Telisotuzumab-Vedotin (Teliso-V) for Patients with Previously Treated Non-Small Cell Lung Cancer

CEO

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령